Translational vitreous proteomics

Proteomics - Clinical Applications

Volumn 8, Issue 3-4, 2014, Pages 204-208

  Mahajan, Vinit B ^a,b   Skeie, Jessica M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Retina; Vitrectomy; Vitreoretinopathy; Vitreous

Indexed keywords

ALBUMIN; COLLAGEN; CYTOKINE; ENZYME; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN D2 SYNTHASE; PROSTAGLANDIN SYNTHASE; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALGORITHM; ANATOMICAL CONCEPTS; ARTICLE; BIOINFORMATICS; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEOMICS; TRANSLATIONAL RESEARCH; UVEITIS; VITREORETINOPATHY; VITREOUS BIOPSY; VITREOUS BODY; WESTERN BLOTTING; BIOLOGY; EXTRACELLULAR MATRIX; GENETICS; METABOLISM; PROCEDURES;

COMPUTATIONAL BIOLOGY; EXTRACELLULAR MATRIX; HUMANS; MASS SPECTROMETRY; PRECISION MEDICINE; PROTEIN ARRAY ANALYSIS; PROTEOMICS; VITREOUS BODY;

EID: 84898403861     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300062     Document Type: Article

References (44)

1. Grus, F. H., Joachim, S. C., Pfeiffer, N., Proteomics in ocular fluids. Proteomics Clin. Appl. 2007, 1, 876-888.
2. Bishop, P. N., Structural macromolecules and supramolecular organisation of the vitreous gel. Prog. Retin. Eye Res. 2000, 19, 323-344.
3. Aliyar, H. A., Foster, W., Hamilton, P. D., Ravi, N., Towards the development of an artificial human vitreous. Polymer Prepr. 2004, 45, 469-470.
4. Sebag, J., Molecular biology of pharmacologic vitreolysis. Trans. Am. Ophthalmol. Soc. 2005, 103, 473-494.
5. Hong, J., Deng, S. X., Xu, J., Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N. Engl. J. Med. 2012, 367, 2053; author reply 2054.
6. Skeie, J. M., Mahajan, V. B., Dissection of human vitreous body elements for proteomic analysis. J. Vis. Exp. 2011, 47, 2455.
7. Funaki, H., Sawaguchi, S., Yaoeda, K., Koyama, Y. et al., Expression and localization of angiogenic inhibitory factor, chondromodulin-I, in adult rat eye. Invest. Ophthalmol. Vis. Sci. 2001, 42, 1193-1200.
8. Halfter, W., Dong, S., Dong, A., Eller, A. W., Nischt, R., Origin and turnover of ECM proteins from the inner limiting membrane and vitreous body. Eye (Lond) 2008, 22, 1207-1213.
9. Zhou, R., Caspi, R. R., Ocular immune privilege. F1000 Biol. Rep. 2010, 2, 3.
10. Zhou, M., Lucas, D. A., Chan, K. C., Issaq, H. J. et al., An investigation into the human serum "interactome". Electrophoresis 2004, 25, 1289-1298.
11. Gao, B. B., Chen, X., Timothy, N., Aiello, L. P., Feener, E. P., Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J. Proteome Res. 2008, 7, 2516-2525.
12. Takano, A., Hirata, A., Inomata, Y., Kawaji, T. et al., Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am. J. Ophthalmol. 2005, 140, 654-660.
13. Mitamura, Y., Takeuchi, S., Matsuda, A., Tagawa, Y. et al., Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy. Am. J. Ophthalmol. 1999, 128, 763-765.
14. Skeie, J. M., Wagner, B. A., Teoh, M. L., Ross, J. et al., Functional validation of proteomics screening: superoxide dismutase-3 regulates oxidative stress in human eyes with diabetic disease. HUPO (Human Proteome Organisation) 11th Annual World Congress, Boston, MA, September 9-13 2012, Poster # 223.
15. Wang, H., Feng, L., Hu, J., Xie, C., Wang, F., Differentiating vitreous proteomes in proliferative diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass spectrometry. Exp. Eye Res. 2013, 108, 110-119.
16. Skeie, J. M., Brown, E. N., Martinez, H. D., Russell, S. R. et al., Proteomic analysis of vitreous biopsy techniques. Retina 2012, 32, 2141-2149.
17. Pfahler, S. M., Brandford, A. N., Glaser, B. M., A prospective study of in-office diagnostic vitreous sampling in patients with vitreoretinal pathology. Retina 2009, 29, 1032-1035.
18. Ecker, S. M., Hines, J. C., Pfahler, S. M., Glaser, B. M., Aqueous cytokine and growth factor levels do not reliably reflect those levels found in the vitreous. Mol. Vis. 2011, 17, 2856-2863.
19. Davuluri, G., Espina, V., Petricoin, 3rd, E. F., Ross, M. et al., Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch. Ophthalmol. 2009, 127, 613-621.
20. Ecker, S. M., Pfahler, S. M., Hines, J. C., Lovelace, A. S., Glaser, B. M., Sequential in-office vitreous aspirates demonstrate vitreous matrix metalloproteinase 9 levels correlate with the amount of subretinal fluid in eyes with wet age-related macular degeneration. Mol. Vis. 2012, 18, 1658-1667.
21. Los, L. I., van der Worp, R. J., van Luyn, M. J., Hooymans, J. M., Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest. Ophthalmol. Vis. Sci. 2003, 44, 2828-2833.
22. Walia, S., Clermont, A. C., Gao, B. B., Aiello, L. P., Feener, E. P., Vitreous proteomics and diabetic retinopathy. Semin. Ophthalmol. 2010, 25, 289-294.
23. Yu, J., Liu, F., Cui, S. J., Liu, Y. et al., Vitreous proteomic analysis of proliferative vitreoretinopathy. Proteomics 2008, 8, 3667-3678.
24. Funatsu, H., Yamashita, T., Yamashita, H., Vitreous fluid biomarkers. Adv. Clin. Chem. 2006, 42, 111-166.
25. Loukovaara, S., Robciuc, A., Holopainen, J. M., Lehti, K. et al., Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol. (Copenh.) 2012, 91, 531-539.
26. Mohan, N., Monickaraj, F., Balasubramanyam, M., Rema, M., Mohan, V., Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J. Diabetes Complications 2012, 26, 435-441.
27. Yoshimura, T., Sonoda, K. H., Sugahara, M., Mochizuki, Y. et al., Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE 2009, 4, e8158.
28. Fong, A. H., Lai, T. Y., Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin. Interv. Aging 2013, 8, 467-483.
29. Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S. et al., Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012, 119, 789-801.
30. Yamane, K., Minamoto, A., Yamashita, H., Takamura, H. et al., Proteome analysis of human vitreous proteins. Mol. Cell. Proteomics 2003, 2, 1177-1187.
31. Citirik, M., Kabatas, E. U., Batman, C., Akin, K. O., Kabatas, N., Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy. Ophthalmic Res. 2012, 47, 7-12.
32. Ozkan, E., Carrillo, R. A., Eastman, C. L., Weiszmann, R. et al., An extracellular interactome of immunoglobulin and lrr proteins reveals receptor-ligand networks. Cell 2013, 154, 228-239.
33. Gao, B. B., Clermont, A., Rook, S., Fonda, S. J. et al., Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 2007, 13, 181-188.
34. Mahajan, V. B., Skeie, J. M., Assefnia, A. H., Mahajan, M., Tsang, S. H., Mouse eye enucleation for remote high-throughput phenotyping. J. Vis. Exp. 2011, 57, 3184.
35. Leung, L. S. B., Voleti, V. B., Lin, J. H., Tsang, S. H., in: Traboulsi, E. I. (Ed.), Genetic Diseases of the Eye, Oxford University Press, New York 2012, pp. 356-372.
36. Utriainen, A., Sormunen, R., Kettunen, M., Carvalhaes, L. S. et al., Structurally altered basement membranes and hydrocephalus in a type XVIII collagen deficient mouse line. Hum. Mol. Genet. 2004, 13, 2089-2099.
37. Skeie, J. M., Tsang, S. H., Mahajan, V. B., Evisceration of mouse vitreous and retina for proteomic analyses. J. Vis. Exp. 2011, 50, 2795.
38. Skeie, J. M., Tsang, S. H., Mahajan, V. B., Mouse Vitreoretinal Proteome [ARVO Abstract]. Invest. Ophthalmol. Vis. Sci. 2013, 54, e-Abstract 2465.
39. Lee, R. W., Dick, A. D., Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond) 2012, 26, 17-28.
40. Tlucek, P. S., Folk, J. C., Sobol, W. M., Mahajan, V. B., Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy. Clin. Ophthalmol. 2013, 7, 1093-1098.
41. Tlucek, P. S., Folk, J. C., Orien, J. A., Stone, E. M., Mahajan, V. B., Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy. Arch. Ophthalmol. 2012, 130, 1395-1401.
42. Hauck, S. M., Dietter, J., Kramer, R. L., Hofmaier, F. et al., Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol. Cell. Proteomics 2010, 9, 2292-2305.
43. Hauck, S. M., Hofmaier, F., Dietter, J., Swadzba, M. E. et al., Label-free LC-MSMS analysis of vitreous from autoimmune uveitis reveals a significant decrease in secreted Wnt signalling inhibitors DKK3 and SFRP2. J. Proteomics 2012, 75, 4545-4554.
44. Mao, L., Yang, P., Hou, S., Li, F., Kijlstra, A., Label-free proteomics reveals decreased expression of CD18 and AKNA in peripheral CD4+ T cells from patients with Vogt-Koyanagi-Harada syndrome. PLoS ONE 2011, 6, e14616.